Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 4/20 | 1.00 |
| ▸ | CA1 | P00915 | 6/20 | 0.74 |
| ▸ | CA2 | P00918 | 6/20 | 0.74 |
| ▸ | ACHE | P22303 | 6/20 | 0.74 |
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975748 | 0.94 | MTNR1A (0.90) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8765749 | 0.92 | MTNR1A (0.85) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8765743 | 0.92 | MTNR1A (0.85) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8766448 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL5526850 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL6523015 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL9669811 | 0.81 | CA1 (0.72) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL12586121 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8056603 | 0.81 | DRD2 (0.68) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8056611 | 0.81 | DRD2 (0.68) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0286516-B1 | Amino-5,6,7,8-tetrahydro-naphtho[2,3b]furan derivatives, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-03-18 | — | — | EP | claimed |
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| EP-1745016-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105737-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | WO | disclosed |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-27 | — | — | US | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4885373-A | AMINE DERVIVATIVES USED AS ANTIDEPRESSANT AND DOPAMINERGIC STIMULANTS | ADIR ET CIE (FR) | 1989-12-05 | — | — | US | disclosed |
| US-4863951-A | ANTIDEPRESSANTS, ANTIAGRESSIVES, DOPAMINERGIC PROPERTIES | ADIR ET CIE (FR) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | TDO2, ITPA, TTI2 | MTNR1A 4194/4885MTNR1B 3845/4885CA1 1674/4885 |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | TDO2, ITPA, TTI2 | MTNR1A 4194/4885MTNR1B 3845/4885CA1 1674/4885 |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | TDO2, TTI2, ITPA | MTNR1A 4200/4885MTNR1B 3824/4885CA1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.